相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Immune Deficiency and Dysregulation Activity (IDDA2.1 'Kaleidoscope') Score and Other Clinical Measures in Inborn Errors of Immunity
Markus G. Seidel et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2022)
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation
Basak Kayaoglu et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2021)
Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity
Jerome Hadjadj et al.
FRONTIERS IN IMMUNOLOGY (2021)
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Donna Przepiorka et al.
ONCOLOGIST (2020)
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score
Victoria Katharina Tesch et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation
Kunihiko Moriya et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Ruxolitinib Response in an Infant with Very-Early-Onset Inflammatory Bowel Disease and Gain-of-Function STAT1 Mutation
Karen P. Acker et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2020)
Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient
Oliver Wegehaupt et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2020)
STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition
Natalia S. Chaimowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Janus Kinase Inhibition in the Aicardi-Goutieres Syndrome
Adeline Vanderver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies
Elisa Cordero et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
JAK Inhibition in the Aicardi-Goutieres Syndrome
Benedicte Neven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
Harinder Gill et al.
ANNALS OF HEMATOLOGY (2019)
STAT1 Gain-of-Function Mutations Cause High Total STAT1 Levels With Normal Dephosphorylation
Ofer Zimmerman et al.
FRONTIERS IN IMMUNOLOGY (2019)
A journey through infectious risk associated with ruxolitinib
Emanuela Sant'Antonio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib
Tariq Al Shehri et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2019)
Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy
Lauren Bowen Reoma et al.
ANNALS OF NEUROLOGY (2019)
Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)
Kornvalee Meesilpavikkai et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations
Jennifer W. Leiding et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
Alexander Vargas-Hernandez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Marketa Bloomfield et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
Lisa R. Forbes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
Katja G. Weinacht et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Fatal ruxolitinib-related JC virus meningitis
Begona Ballesta et al.
JOURNAL OF NEUROVIROLOGY (2017)
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
Iram Saeed et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
Julie Toubiana et al.
BLOOD (2016)
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Mignon L. Loh et al.
PEDIATRIC BLOOD & CANCER (2015)
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
G. Caocci et al.
LEUKEMIA (2014)
Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
Rowan Wathes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
Roger A. Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Biology and significance of the JAK/STAT signalling pathways
Hiu Kiu et al.
GROWTH FACTORS (2012)
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
Luyan Liu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis
Frank L. van de Veerdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
分享论文
